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This investigation describes the formulation and characterization of rheologically structured vehicles (RSVs)
designed for improved drug delivery to the vagina. Interactive, multicomponent, polymeric platforms were
manufactured containing hydroxyethylcellulose (HEC, 5% w/w) polyvinylpyrrolidone (PVP, 4% w/w), Pluronic
(PL, 0 or 10% w/w), and either polycarbophil (PC, 3% w/w) or poly(methylvinylether-co-maleic anhydride)
(Gantrez S97, 3% w/w) as a mucoadhesive agent. The rheological (torsional and dynamic), mechanical (com-
pressional), and mucoadhesive properties were characterized and shown to be dependent upon the mucoadhesive
agent used and the inclusion/exclusion of PL. The dynamic rheological properties of the gel platforms were also
assessed following dilution with simulated vaginal ﬂuid (to mimic in vivo dilution). RSVs containing PC were
more rheologically structured than comparator formulations containing GAN. This trend was also reﬂected in
formulation hardness, compressibility, consistency, and syringeability. Moreover, formulations containing PL (10%
w/w) were more rheologically structured than formulations devoid of PL. Dilution with simulated vaginal ﬂuids
signiﬁcantly decreased rheological structure, although RSVs still retained a highly elastic structure (G′ > G′′ and
tan δ < 1). Furthermore, RSVs exhibited sustained drug release properties that were shown to be dependent upon
their rheological structure. It is considered that these semisolid drug delivery systems may be useful as site-
retentive platforms for the sustained delivery of therapeutic agents to the vagina.
Introduction
The majority of new human immunodeﬁciency virus (HIV)
infections occur via mucosal transmission during heterosexual
intercourse.
1 Vaginally administered HIV microbicide and
mucosal vaccine strategies are being investigated as a promising
means of preventing HIV infection. One of the most logical
and, hence, widely reported approaches to vaginal delivery of
active agents is the use of topically applied bioactive semisolids
that have been shown to be highly effective in treating/
preventing local diseases.
2-4 Although conventional semisolids
have found extensive use as vaginal drug delivery platforms
due to their low cost and ease of use, they also suffer from
relatively low patient acceptability and poor vaginal retention,
5,6
such that optimal delivery of therapeutic agents to the vagina
remains a signiﬁcant challenge. For example, it is understood
that development of practical semisolid drug delivery platforms
for vaginal application requires a fundamental understanding
of their rheological, textural, and mucoadhesive properties within
the vaginal vault.
7
Of signiﬁcant interest are the structural rheological properties
of vaginal semisolids at equilibrium (low stresses/strains),
particularly given the effect these may have on drug release
properties and passive seepage between epithelial surfaces.
Moreover, the ﬂow rheological properties are of primary interest
because they have been shown to largely govern the ease of
application and dispersion of semisolids. Moreover, prolonged
retention at the site of application leading to increased thera-
peutic efﬁcacy may be achieved through knowledge of the
mucoadhesive properties of the semisolid.
2 Mucoadhesion is
particularly relevant because the self-cleansing mechanisms
within the vagina, in addition to normal physiological functions,
may limit the extent of contact between the vaginal mucosa
and the applied semisolid. In an attempt to overcome the
problems associated with poor retention and vaginal leakage,
mucoadhesive polymers that offer the possibility of enhanced
product retention and, thus, sustained delivery have received
considerable attention.
8-10
While simple, monopolymeric component systems may
provide useful “ﬁrst generation” platforms, enhanced functional-
ity may be attained through the use of more complex multi-
component polymeric semisolids that offer high degrees of
mucoadhesion and rheological structure to provide optimized
retention under in vivo conditions. Ideally, a vaginal semisolid
should possess suitable properties to facilitate application yet
offer sufﬁcient elastic structure in vivo to provide sustained drug
delivery and enhanced retention.
11 Moreover, these drug delivery
platforms should maintain rheological structure in vivo during
usage (ambulation, seepage between epithelial surfaces, and
during sexual intercourse) and following dilution with vaginal
ﬂuid.
Consequently, a logical yet previously unreported approach
that may signiﬁcantly improve the in vivo performance of
vaginal semisolids would be to formulate rheologically struc-
tured platforms using multiple polymers so as to provide both
an enhanced rheological structure and mucoadhesive character.
This study investigates the use of rheologically structured
vehicles (RSVs) in which structural synergy may be achieved
due to polymer-polymer interactions.
12 Moreover, through
judicious choice of the polymeric components, RSVs may be
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allowing interpenetration of the ﬂuidized polymer chains with
mucus and, hence, ensuring maximum physical and chemical
adhesion.
13
Given the complexity of RSV formulations and the range of
shearing stresses experienced by these semisolids in vivo,
characterization should involve a comprehensive rheological
evaluation. The selection of semisolids intended for this purpose
should be performed in the context of the rheological demands
of these systems such that the presence of diluting vaginal ﬂuids
and the inherent effects on the rheological properties should
be assessed. This would thereby provide an indication of the
possible persistence of the rheological structure in vivo. The
aim of this study is to characterize the rheological, mucoadhesive
and compressional ﬂow (textural) properties of RSV formula-
tions to facilitate the development of novel vaginal semisolid
delivery platforms. In so doing, we aim to achieve semisolids
that enhance retention within the vagina to provide a platform
suitable for the controlled delivery of therapeutic agents.
Materials and Methods
Materials. Poly(methylvinylether-co-maleic anhydride) (Gantrez
S97) and polyvinylpyrollidone (Plasdone K-90, Mv 1.3 M) were kindly
donated by International Specialty Products (Ohio, U.S.A.). Hydroxy-
ethylcellulose (Natrosol 250-HHX-Pharm, Mv 1.3 M, DS 2.0) and
polycarbophil (Noveon AA1, a divinyl glycol cross-linked poly(acrylic
acid)) were also kindly donated by Aqualon (Warrington, U.K.) and
Noveon Pharma GmbH & Co KG (Raubling, Germany), respectively.
Pluronic (Lutrol F127, a copolymer of polyoxyethylene and polyox-
ypropylene, Mv 12600) was purchased from BTC Specialty Chemical
Distribution Limited (Cheshire, U.K.). Erioglaucine disodium salt
(792.85 MW) was purchased from Sigma (Poole, Dorset, U.K.). Replens
was supplied by AAH Hospital Service (Belfast, U.K.). Replens is a
commercially available vaginal moisturizer containing carbomer 934P,
glycerin, hydrogenated palm oil glyceride, mineral oil, polycarbophil,
puriﬁed water, and sorbic acid. All other chemicals were purchased
from Sigma (Poole, Dorset, U.K.) and were of AnalaR grade or
equivalent quality.
Preparation of Rheologically Structured Vehicles (RSV). Sorbic
acid (0.1% w/w) and the required amount of sodium hydroxide to
achieve a ﬁnal pH ) 6 were added to water in a HiVac mixing bowl
(Summit Medical, Gloucestershire, U.K.). The mucoadhesive compo-
nent, polycarbophil or poly(methylvinylether-co-maleic anhydride) (PC
or Gantrez; 3% w/w), was subsequently introduced and mixed under
vacuum. Following complete dissolution of the mucoadhesive com-
ponent, Pluronic F127 (PL; 0 or 10% w/w), hydroxyethylcellulose
(HEC; 5% w/w), and polyvinylpyrrolidone (PVP; 4% w/w) were added
in a stepwise fashion and mixed under vacuum. To remove all entrapped
air, formulations were transferred to McCartney bottles, gently centri-
fuged, and stored at 4 °C for 48 h prior to testing. Formulations
containing erioglaucine (100 µg per 3 g dose) were prepared using a
similar method with the exception that erioglaucine was added to the
aqueous phase (1.36 mL of 11.18 mg/mL) prior to addition of F127.
Preparation of Simulated Vaginal Fluid. For the purposes of gel
dilution studies, simulated vaginal ﬂuid (SVF) was prepared as
described by Owen and Katz.
14 NaCl (3.51 g), KOH (1.40 g), Ca(OH)2
(0.222 g), bovine serum albumin (0.018 g), lactic acid (2 g), acetic
acid (1 g), glycerol (0.16 g), urea (0.4 g), and glucose (5 g) were
dissolved in1Lo fdeionized water, followed by adjustment to pH 4.2
with HCl.
In Vitro Evaluation of Mucoadhesion. The mucoadhesive proper-
ties of RSVs were determined using a TA-XT2 Texture Analyzer
(Stable Microsystems, Surrey, England) and a previously described
mucin disk test.
15 In summary, porcine mucin discs (250 mg, 13 mm
diameter), prepared by direct compression (10 tonne, 30s), were
horizontally attached onto the lower face of an inert horizontal poly-
carbonate probe and immersed in a mucin solution (5% w/w) for 30s.
The mucin disk was brought into contact with the formulation under
examination and a force of 1 N was then applied for 30 s to ensure
intimate contact between the disk and formulation. The probe was then
elevated at a speed of 1.0 mm/s, and the mucoadhesive strength was
determined from the force of detachment.
Measurement of Work of Syringeability. The work done to expel
formulations from a model vaginal applicator was determined using a
TA-XT2 Texture Analyzer in compression mode. RSVs (3 g) were
packed into a model applicator and an inert polycarbonate probe was
used to expel the syringe contents at a rate of 2.0 mm/s through a
distance of 30 mm. The work done to expel the syringe contents was
calculated from the area under the resultant force-time plot. In addition
to RSVs, a commercially available formulation, Replens was also
studied for comparison purposes.
Texture Proﬁle Analysis (TPA). The compressional ﬂow (hardness
and compressibility) properties of RSV formulations were determined
using a TA-XT2 Texture Analyzer in compression mode, as described
previously.
15 In brief, samples (16 g) were packed into identical
McCartney bottles and centrifuged to remove entrapped air. An
analytical probe (10 mm diameter) was compressed twice into each
formulation at a deﬁned rate (2 mm/s) to a deﬁned depth (15 mm),
allowing a 15 s delay period between the end of the ﬁrst and beginning
of the second compression. From the resultant force-time plot the
mechanical parameters including hardness (the force required to attain
a given deformation) and compressibility (the work required to deform
the formulation during the ﬁrst compression of the probe) were derived.
Rheological (Dynamic) Analysis. Oscillatory (dynamic) rheometry
was conducted using an AR2000 rheometer (T.A. Instruments, Surrey,
England) at 25 ( 0.1 °C usinga2c mdiameter parallel plate geometry
and a gap of 1000 µm, as previously reported.
16 Samples were carefully
applied to the lower stationary plate and the upper plate was adjusted
to the predeﬁned gap size. Formulations were then retained for an
equilibrium period to facilitate relaxation of internal stresses introduced
during sample loading. During testing, samples were subjected to a
predetermined oscillatory stress value (selected from within the linear
viscoelastic region) over a frequency range from 0.1 to 10 Hz.
Calculation of the storage modulus (G′), loss modulus (G′′), loss tangent
(tan δ), and dynamic viscosity (n′) were performed using proprietary
software (TA Instruments, Leatherhead, England).
In Vitro Gel Dilution. Given that vaginal semisolids will experience
dilution in vivo it is important to characterize this effect by dilution of
the prepared RSVs with simulated vaginal ﬂuid (SVF). In summary, a
deﬁned mass (3 g) of RSV was thoroughly mixed in a HiVac mixing
bowl (Summit Medical, Gloucestershire, U.K.) with 0.1, 0.3, 0.5, 0.7,
and 0.9 mL of SVF. Gels were transferred to McCartney bottles, gently
centrifuged to remove entrapped air and storage at +4 °C for 24 h
prior to dynamic rheological analysis (37 °C). The dilution ratio was
selected to represent that normally encountered in the vagina following
insertion of the delivery vehicle.
17
Flow Analysis under Continuous Shear. Flow rheometry was
conducted at 25 ( 0.1 °C using an AR 2000 rotational rheometer
operating in continuous ﬂow mode using a parallel plate and a constant
gap of 1000 µm. Sample geometry (2, 4, or 6 cm plate) was selected
according to formulation consistency. Flow rheology was conducted
using a loop test in which the shearing rate was increased gradually
from a minimum (0.001 s-1) up to a predetermined maximum (2 s-1)
within 60 s and then returned to the starting shear rate under the same
conditions. For comparison purposes, the commercially available
vaginal gel, Replens, was also studied. Modeling of the ﬂow properties
of the various formulations was performed using the Ostwald-de Waele
equation, as follows:
where σ is the shearing stress, γ ˙ is the rate of shear, k is the consistency,
and n is the pseudoplastic index.
σ ) kγ ˙
n (1)
2428 Biomacromolecules, Vol. 10, No. 9, 2009 Andrews et al.In Vitro Release of Erioglaucine from RSVs. A deﬁned mass (5
g, n ) 6) of each formulation was placed in a cylindrical vessel and
anchored at the bottom of a stoppered 100 mL glass vial containing 50
mL of SVF, and the glass containers were placed in a shaking orbital
incubator (Sanyo Gallenkamp, 100 rpm) maintained at 37 °C. The
release medium was sampled (7 mL) at predetermined time intervals
and analyzed by UV spectroscopy at 630 nm. At each sample point an
equal volume of fresh prewarmed dissolution media was added to the
dissolution vessels to replace the volume sampled. The mass of
erioglaucine (EG) released was calculated with reference to a calibra-
tion curve (concentration range 0-8 mg/mL, r > 0.999).
Statistical Analysis. The effect of mucoadhesive type (PC or Gantrez
S97) and PL concentration (0-10% w/w) on the mucoadhesive bond
strength, percent release at 2, 6, and 24 h, syringeability, viscoelastic
properties at deﬁned representative frequencies (0.06, 0.27, 0.53, 0.74,
1.0 Hz) and mechanical (compressional ﬂow) properties (hardness,
compressibility) were statistically compared using a one-way ANOVA
(Statview, Abacus Concepts, CA). In all cases, posthoc comparisons
of the means of individual groups (following the ANOVA) were
performed using Tukey’s Honestly Signiﬁcant Difference test. A
signiﬁcance level of p < 0.05 was accepted to denote signiﬁcance in
all cases.
Results
The variation in elastic and viscous modulus for each RSV
formulation as a function of oscillatory frequency are illustrated
in the representative rheograms shown in Figures 1 and 2,
respectively, while the loss tangent and dynamic viscosities at
ﬁve selected oscillatory frequencies are presented in Table 1.
RSVs containing PC had a signiﬁcantly greater G′, G′′, and η′
and a signiﬁcantly lower loss tangent than comparator formula-
tions containing Gantrez S97. Also, formulations containing PL
were more rheologically structured (statistically higher G′, G′′,
and η′ and lower tan δ) than formulations devoid of PL.
Typically, physically entangled polymer gels exhibit storage and
loss moduli that increase as a function of oscillatory frequency.
However, RSVs exhibited relatively small increases in the
storage and loss moduli as a function of oscillatory frequency.
Interestingly, those formulations devoid of PL had a loss tangent
that was signiﬁcantly inﬂuenced by oscillatory frequency,
whereas those formulations containing PL had a frequency
independent loss tangent at oscillatory frequencies greater than
3 Hz. In addition, the storage modulus for all formulations was
signiﬁcantly higher than the loss modulus and, thus, the loss
tangent (ratio of G′′/G′) was less than one.
The frequency dependence of the storage modulus was ﬁtted
to a general power law expression as follows (eq 2).
In this model, Gf refers to the storage modulus (G) at a speciﬁed
oscillatory frequency, k is the oscillatory consistency, f is the
oscillatory frequency, and n is the oscillatory exponent.
The data obtained from this analysis is shown in Table 1 for
all RSV systems and for the comparator single component
systems. It was not possible to obtain oscillatory rheograms for
the single polymeric component systems (PVP, Gantrez and PL)
at the concentrations used, 4% w/w, 3% w/w and 10% w/w,
respectively. Signiﬁcant decreases in the oscillatory exponent
(n) were observed as the mucoadhesive was changed from
Gantrez S97 to PC (most notable in formulations devoid of PL),
and upon the addition of PL. Moreover, the oscillatory exponent
of 5% w/w HEC, the rheological structure building component,
was statistically greater than that observed for any RSV. The
oscillatory consistency values of the RSVs were affected by
the addition of PL and the choice of mucoadhesive component.
Formulations containing Gantrez S97 had a signiﬁcantly lower
oscillatory consistency than those RSVs containing PC, whereas
the addition of PL signiﬁcantly increased the oscillatory
consistency. For the monopolymeric systems, HEC 5% w/w was
shown to have a greater consistency than PC 3% w/w, whereas
the oscillatory exponent (n) of PC 3% w/w was statistically
lower than that obtained for HEC 5% w/w.
The temperature dependence of the storage modulus for the
two RSVs containing PL is shown in Figure 3. The graph for
the single component PL 10% w/w gel is not presented because
it did not show a sol-gel transition temperature over the range
10-50 °C. There is a distinct increase in the storage modulus
of the two formulations as a function of temperature with an
obvious sol-gel transition temperature occurring at approxi-
Figure 1. Effect of increasing oscillatory frequency on the storage
modulus (G′) of RSV formulations containing ([) HEC 5%/PC 3%/
PL 10%/PVP 4% (w/w); (∆) HEC 5%/GANT 3%/PL 10%/PVP 4%
(w/w); (9) HEC 5%/PC 3%/PVP 4% (w/w); (×) HEC 5%/GANT 3%/
PVP 4% (w/w); (s) HEC 5%; ()) PC 3% (w/w). Each value is the
average of at least ﬁve replicates. Standard deviations have been
omitted for clarity, however, and in all cases, the coefﬁcient of variance
was less than 4%.
Figure 2. Effect of increasing oscillatory frequency on the loss
modulus (G′′) of RSV formulations containing ([) HEC 5%/PC 3%/
PL 10%/PVP 4% (w/w); (∆) HEC 5%/GANT 3%/PL 10%/PVP 4%
(w/w); (9) HEC 5%/PC 3%/PVP 4% (w/w); (×) HEC 5%/GANT 3%/
PVP 4% (w/w); (s) HEC 5%; ()) PC 3% (w/w). Each value is the
average of at least ﬁve replicates. Standard deviations have been
omitted for clarity, however, and in all cases, the coefﬁcient of variance
was less than 6%.
Gf ) kf
n (2)
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2430 Biomacromolecules, Vol. 10, No. 9, 2009 Andrews et al.mately 16 °C. The formulation containing Gantrez S97 had a
storage modulus that was signiﬁcantly lower than PC in the
gel state (temperatures above 16 °C) and in the lower temper-
ature sol state.
The effects of dilution with SVF on the rheological properties
of the four RSV systems are demonstrated in Figure 4a-d. The
ratios of the storage moduli of the diluted RSV systems (0.1-0.9
mL dilution) to that of their undiluted counterparts, across the
frequency range investigated (0.1-10 Hz), are displayed. All
formulations displayed a signiﬁcant loss of storage modulus
upon dilution. A signiﬁcantly lower ratio of G′gel+SVF/G′gel and,
hence, decreased rheological structure was observed for all RSVs
as the volume of SVF increased (from 0.1-0.9 mL). The ratio
of the storage modulus of the diluted binary gels to the undiluted
counterparts decreased when PC was substituted for Gantrez
S97. Interestingly, the addition of PL to PC containing RSVs
resulted in a formulation that was more robust to dilution at
low SVF volume (0.1 mL), whereas at greater volumes (0.3-0.9
mL), the PC formulation devoid of PL was more capable of
maintaining rheological structure. For RSVs containing Gantrez
S97, at low SVF volume (0.1 mL) there was no signiﬁcant
difference between formulations containing and devoid of PL
whereas at higher volumes (0.3-0.9 mL) formulations contain-
ing PL were more resistant to dilution. The RSVs containing
PC (and devoid of PL) exhibited the highest ratio of diluted
gel to gel and, hence, the greatest rheological structure following
dilution at the maximum SVF volume (0.9 mL), whereas the
lowest ratio was observed for the RSV containing 5% w/w HEC,
3% w/w Gantrez S97, and 4% w/w PVP (Figure 5).
All formulations displayed a nonlinear relationship between
the shear stress and shear strain and, hence, a shear viscosity
that decreased with increasing shear rate (pseudoplastic). In
addition to being pseudoplastic, a shift in the upward and
downward ﬂow curves was observed, suggesting thixotropic
behavior (data not shown). Decreases in viscosity as a function
of increasing shear rate may be described in terms of shear stress
and shear rate using an exponential function, referred to as the
Ostwald-de Waele rheological expression (eq 1). This model
has been shown to be appropriate for the physical characteriza-
tion of many different materials,
18 providing information
regarding the ﬂow consistency (K) of the material, and that is
an indication of the strength and structure of the material.
Therefore, as the viscosity of the sample increases so will the
consistency.
17 K may therefore be used to establish the effect
of changes in formulation variables on material structure at a
single shear rate value (1 s-1). In this study we have investigated
the effect of various mucoadhesive components (PC and Gantrez
S97) and the inclusion of a thermogelling polymer (PL) on the
rheological (destructive and transient), compressional ﬂow
(hardness and compressibility), and drug release properties of
RSVs. In relation to ﬂow rheology, changing the mucoadhesive
from PC to Gantrez S97 signiﬁcantly reduced RSV ﬂow
consistency, whereas there was no signiﬁcant effect on the
ﬂow properties of RSVs upon the addition of PL (Table 1).
The ﬂow properties of a commercially available vaginal gel
(Replens) was examined as a comparator to the RSV systems.
Replens was shown to have a statistically lower consistency
value (Table 1).
The formulations examined within this study displayed a wide
range of mechanical and mucoadhesive properties that were
signiﬁcantly affected by changing the mucoadhesive polymer
(Table 1). RSVs containing Gantrez S97 were more mucoad-
hesive than their PC counterparts. There was shown to be no
signiﬁcant difference in the mucoadhesive bond strength upon
the addition of PL, however, all RSVs had a greater mucoad-
hesive ability than Replens. Formulations containing PC as the
mucoadhesive component had signiﬁcantly greater syringeabil-
ity, hardness, and compressibility values than those formulations
manufactured using Gantrez S97. As observed during ﬂow
analyses, the addition of PL had no signiﬁcant effect on the
syringeability and the mechanical properties (hardness and
compressibility) of the RSV systems. The syringeability and
mucoadhesive strength of Replens was much lower (statistically
signiﬁcant) than all RSV systems.
The release of a model compound, EG, as a function of time
from the four RSV systems over a 24 h period is illustrated in
Figure 6. The percentage EG released at 2, 6, and 24 h is also
shown in Table 1. All gel systems displayed sustained release
over the observed time period. The percentage released was
signiﬁcantly affected by the mucoadhesive component added
to the formulation. For example, formulations containing PC
released a lower percentage of total EG content compared to
those containing Gantrez S97. Interestingly, the inclusion of PL
had a signiﬁcant effect on release for RSVs containing PC with
the formulation containing 5% HEC, 10% PL, 4% PVP, and
3% PC displaying the slowest percent release. There was no
statistical difference in the percentage of EG released between
the two Gantrez S97 formulations. In an attempt to determine
the mechanism by which the EG was released from the RSVs,
a simple, semiempirical power law equation (eq 3)
19 to describe
the release data was employed. Release data was ﬁtted to the
general release equation
20 using a double logarithmic transfor-
mation and subsequent least-squares regression. Modeling the
release data using the Power law expression yielded release
exponents ranging from 0.74-0.84, indicative of an anomalous
transport mechanism.
Mt/M∞ is the absolute cumulative amount of drug released at
time t and inﬁnite time, respectively, K is a constant incorporat-
ing structural and geometric characteristics, and n is the release
exponent, which is indicative of the mechanism of release.
Discussion
Polymer gel systems are widely used to formulate pharma-
ceutical drug products and have been employed in dental,
21
Figure 3. Temperature dependence of the storage modulus of the
two RSV formulations containing PL, (9) HEC 5%/PC 3%/PL 10%/
PVP 4% (w/w); (∆) HEC 5%/GANT 3%/PL 10%/PVP 4% (w/w). Each
value is the average of at least ﬁve replicates. Standard deviations
have been omitted for clarity, however, and in all cases, the coefﬁcient
of variance was less than 5%.
Mt/M∞ ) Kt
n (3)
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22 vaginal,
17 and ophthalmic applications.
23
Typically, these systems are easy to apply, offer enhanced
patient compliance, and, in the case of aqueous-based systems,
display reduced irritancy, which is essential for application to
mucous membranes.
24 However, in the case of vaginal admin-
istration, gel mixing with cervicovaginal ﬂuid and semen causes
gel dilution and contributes to leakage of the formulation.
25
Retention of vaginal gels may be improved using mucoadhesive
polymers, such as those based on poly(acrylic acid) or cellulose
derivatives.
10,17 Although offering increased mucoadhesion,
the rheological properties of these monopolymeric systems are
usually insufﬁcient to offer resistance to in vivo stresses, and
hence, clinical performance is often suboptimal. The rheological
and mechanical properties of vaginal gels should be tailored so
that they are easy to apply (non-Newtonian, shear thinning), be
well dispersed throughout the vaginal vault, and offer extended
residence time to allow for controlled drug delivery.
17 It has
been previously reported that optimal performance (controlled
drug release and maximum retention) may be achieved for gel-
based formulations where a high elastic modulus (exceeding
the loss modulus) is maintained following dilution with vaginal
ﬂuids.
26 In this study, mucoadhesive, site-retentive RSV for-
Figure 4. Frequency dependence of the ratio of the storage modulus of RSVs after and before dilution (G′gel + SVF/G′gel) with (9) 0.1 mL SVF per
3 g RSV; (4) 0.3 mL SVF per 3 g RSV; (×) 0.5 mL SVF per 3 g RSV; (-) 0.7 mL SVF per 3 g RSV; (∆) 0.9 mL SVF per 3 g RSV. (a) HEC
5%/PC 3%/PL 10%/PVP 4% (w/w); (b) HEC 5%/PC 3%/PVP 4% (w/w); (c) HEC 5%/GANT 3%/PL 10%/PVP 4% (w/w); (d) HEC 5%/GANT
3%/PVP 4% (w/w). Each value is the average of at least ﬁve replicates. Standard deviations have been omitted for clarity, however, and in all
cases, the coefﬁcient of variance was less than 6%.
Figure 5. Comparison of RSVs after dilution with 0.9 mL SVF; ())
HEC 5%/PC 3%/PL 10%/PVP 4% (w/w); (9) HEC 5%/PC 3%/PVP
4% (w/w); (2) HEC 5%/GANT 3%/PL 10%/PVP 4% (w/w); ([) HEC
5%/GANT 3%/PVP 4% (w/w). Each value is the average of at least
ﬁve replicates. Standard deviations have been omitted for clarity,
however, and in all cases, the coefﬁcient of variance was less than
5%.
2432 Biomacromolecules, Vol. 10, No. 9, 2009 Andrews et al.mulations, comprising multipolymeric components, have been
developed for sustained vaginal delivery of therapeutics agents.
The relationship between the nondestructive rheological
parameters of gels and oscillatory frequency is often described
using the Maxwell model.
27 Typically, the storage modulus will
dominate the loss modulus at high oscillatory frequencies
whereas at low frequency, viscous behavior will be the dominant
relaxation process. Within this study, the storage (G′) and loss
moduli (G′′) increased as a function of frequency. However,
the extent of increase was small (n values in Table 1 tended
toward zero). The response of the moduli to increasing oscil-
latory frequency was characteristic of the plateau region more
often observed in chemically cross-linked systems.
16 All of the
gels had storage moduli that exceeded the loss moduli (loss
tangent < 1) and none displayed ﬂuid (loss tangent > 1) or ﬂuid/
gel (loss tangent ∼ 1) transition states.
28 The observed rheo-
logical response for RSVs may be attributed to signiﬁcant
physical interaction between the polymeric components, the
formation of an enhanced physical network and hence an
increased elastic response.
21 Moreover, the response of the RSVs
to nondestructive stresses suggests the presence of a three-
dimensional structure formed through the interpenetration of
polymer chains and the formation of secondary interactions.
The physical response of a semisolid to external forces may
be used to characterize the rheological behavior of polymer
gels.
29 The frequency dependence of the storage and loss moduli
is probably the most common technique used to identify the
gel state. The presence of a plateau in the real part of the
complex modulus (G′) that extends over an appreciable window
of frequencies is a typical characteristic of viscoelastic solids.
30
Although the formulations studied in this investigation did not
display a plateau in the mechanical spectra, the dependence of
the storage moduli to oscillatory frequency was low and tended
toward zero (n e 0.27), a characteristic of polymer gels with a
high level of interpenetration and entanglement between polymer
chains.
26 Interestingly, the magnitude of the slope decreased
after the addition of PL and when the mucoadhesive component
was changed from Gantrez S97 to PC. In this study two different
mucoadhesive components were used, Gantrez S97 and PC.
Gantrez S97 is a linear polymer and possesses polymer cross-
links in the gel state that are controlled by polymer chain overlap
and secondary interactions such as hydrogen bonding.
29 Con-
versely, PC is a chemically cross-linked poly(acrylic acid) and
hence the storage modulus is not highly dependent upon
oscillatory frequency. Although the oscillatory consistency of
PC 3% w/w was signiﬁcantly lower than all other polymers (K
) 876.32 ( 4.44), the magnitude of the slope was extremely
low (n ) 0.05 ( 0.01). Therefore, the slopes of the storage
moduli of the RSVs containing PC were signiﬁcantly lower than
Gantrez S97. Furthermore, the inclusion of PL signiﬁcantly
increased the elasticity of the RSV systems and also resulted
in a signiﬁcant decrease in the slope of the storage moduli with
respect to oscillatory frequency. PL (F127) is a long chain,
nonionic triblock copolymer with a central hydrophobic region
of polypropylene oxide (PPO) and two lateral hydrophilic
segments of polyethylene oxide (PEO). These materials have
an ability to undergo temperature-sensitive gelation, whereby
the gel state “collapses” due to aggregation of the PPO segments
upon reaching a critical temperature.
31 At a concentration of
10% w/w, PL did not show a sol-gel transition temperature
over the temperature range examined (10-50 °C) and was
extremely ﬂuid. The addition of PL to the RSVs resulted in a
signiﬁcant increase in the storage modulus, loss modulus and
dynamic viscosity, whereas the loss tangent decreased. Fur-
thermore, the two RSVs containing PL at a loading of 10%
w/w exhibited a distinct sol-gel transition temperature (Figure
3). In situ gelling of polymers has been used extensively for
topical application and provides a convenient method for drug
delivery. Here we have shown that the incorporation of PL
within the RSVs reduces the critical gelation temperature,
causing the formation of gel networks at approximately 16 °C.
This effect may be ascribed to a reduction in the energy required
to cause self-association of the PPO units. Moreover, the
presence of highly entangled overlapping polymer chains,
secondary interactions and permanent primary bonds within
RSVs containing PL has yielded highly elastic rheological
structures, higher than any of the individual polymer components
used in their manufacture. The formation of these advanced gel
systems decreased the dependence of the storage moduli on
oscillatory frequency, enhanced the elastic moduli and generated
in situ gelling properties that have been shown to be advanta-
geous for vaginally administered gels.
32
The most signiﬁcant challenge for topically applied vaginal
gel drug delivery systems is the detrimental effect of dilution
by cervicovaginal ﬂuids (and semen during intercourse) on
formulation rheology and hence on product retention.
33 To
assess this effect, dilution with SVF prior to oscillatory analysis
at 37 °C was conducted. Current vaginal gels, such as those
used in contraceptive applications, tend to be applied using
volumes in the region of 1.5-3 mL. These gel volumes are
typically subjected to dilution by approximately 0.75-1m Lo f
vaginal ﬂuid.
17,34 Accordingly, the effects of dilution, repre-
sentative of that encountered in vivo on the oscillatory properties
of the candidate gel systems were examined by sequentially
diluting3go fR S Vwith up to a maximum of 0.9 mL of SVF.
32
After dilution, all formulations exhibited a G′ that exceeded G′′
and, hence, a loss tangent that was less than 1 in all cases (data
not shown). For each RSV investigated, consecutive dilutions
signiﬁcantly further reduced the storage modulus, although the
effects of dilution on the RSVs in this study were less
pronounced than in previously reported work.
32 This difference
in performance may be directly attributed to a signiﬁcant
interaction between the components used to manufacture the
RSVs, providing robust elastic networks capable of imbibing
considerably larger volumes of vaginal ﬂuid.
26
Previous studies have focused on the effects of dilution by
simulated vaginal ﬂuid and semen simulant on the rheological
Figure 6. Cumulative release proﬁle of erioglaucine from formulations
containing; (9) HEC 5%/PC 3%/PL 10%/PVP 4% (w/w); (2) HEC
5%/PC 3%/PVP 4%; (w/w); (∆) HEC 5%/Gantrez 3%/PL 10/PVP 4%
(w/w); (4) HEC 5%/GANT 3%/PVP 4% (w/w). Each value is the
average ( standard deviation of six replicates.
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performance of vaginal gels, following dilution, across a range
of frequencies has not been comprehensively described. Fol-
lowing administration, a vaginal formulation will experience a
range of stresses across a wide range of time scales.
17 Therefore,
it is important to characterize and understand the time-dependent
rheological behavior of vaginal gels following dilution to closely
mimic in vivo conditions. Following dilution, an ideal response
would be where the formulation preserves its rheological and
mucoadhesive characteristics independent of oscillatory fre-
quency and, hence, independent of the time scale over which
the force is applied. In this study, the RSV platforms investigated
had minimal dependence upon oscillatory frequency. At a
maximum dilution of 0.9 mL, the magnitude of the slope of
G′gel+SVF/G′gel was e0.14. Therefore, these gels could be
expected to maintain structure in vivo due to the presence of a
highly elastic structure and an ability to imbibe ﬂuid with a
limited effect on the rheological structure.
Vaginal gel systems are typically administered via extrusion
using an applicator. Understanding such a process requires a
fundamental knowledge of the rheological behavior after
exposure to complex compressional and torsional shearing
stresses.
26 Moreover, shear-thinning behavior is highly desirable
to aid expulsion from the applicator and ensure adequate
spreading across the vaginal epithelia.
17 It has also been reported
that gels designed for this purpose should possess a high
resistance to deformation following application to minimize the
deleterious effects of dilution and shearing experienced in vivo.
In this investigation we have described the use of mechanical
(texture proﬁle analysis) and ﬂow rheological tests to determine
the compressional and torsional (shear) ﬂow properties of the
RSVs. We have also determined the ease of application of
the RSVs from a syringe applicator. These techniques provide
information on the relative change in material structure over a
wide range of shearing stresses. This may aid in the fundamental
understanding of the effect of physiological stresses on the
formulation structure and the in vivo performance.
35 Addition-
ally, ﬂow rheology may simulate the stresses experienced during
product usage (expulsion from an applicator) that are outside
the linear viscoelastic region. All RSVs displayed a non-
Newtonian pseudoplastic response and a shear viscosity that
decreased with increasing shear rate. This nonlinear effect is
typical of most pharmaceutical gels and arises primarily because
of structural changes induced during the application of shearing
stress. At low shear stresses, the polymer chains within the RSVs
are present in a relaxed state, at concentrations greater than the
critical concentration (c*) for molecular overlap. As the sample
is sheared, polymer chains disentangle and diffuse from the
network, orientating in the direction of shear.
36 Realignment
of the polymer chains enhances mobility and the shear viscosity
decreases. The incorporation of PL had no signiﬁcant effect on
the consistency, hardness, compressibility, and syringeability
of the RSVs, whereas changing the mucoadhesive from PC to
Gantrez S97 signiﬁcantly decreased these properties. The
increased mechanical and ﬂow rheological properties observed
for RSVs containing PC may be attributed to the increased
interaction between the polymeric components in these complex
interactive blends.
The examination of mucoadhesive bond strength involved
the use of a previously reported mucin disk test that deter-
mines the force required to separate a partially hydrated mucin
disk from the surface of the formulation.
15 The ability of a
vaginally applied gel system to adhere to the vaginal epithelium
is essential to maximize residency and, hence, clinical perfor-
mance.
37 The establishment of a mucoadhesive bond between
polymeric components and a biological substrate may be
inﬂuenced by the surface of the biological substrate, the surface
of the bioadhesive layer and the interfacial layer between the
two.
38 Assuming the surface of the mucin disk in each
experiment is similar, then the differences occurring in the
mucoadhesive ability of the polymer systems may be attributed
to formulation surface effects. The RSVs investigated in this
study were designed to provide enhanced retention in the vaginal
vault to provide a means of sustained release of therapeutic
agents to the vaginal mucosal surface. All RSV formulations
exhibited high mucoadhesive bond strength (>0.37 ( 0.04 N,
Table 1), exceeding the value observed for the commercially
available Replens formulation (0.19 ( 0.03 N). HEC has been
reported previously to exhibit moderate mucoadhesive proper-
ties, whereas PC and Gantrez S97 are strongly mucoadhesive.
39,40
In this investigation, the RSV formulations containing Gantrez
S97 were shown to be more mucoadhesive than PC (Table 1).
Given that Gantrez S97 formulations were less elastic this effect
may be attributed to increased diffusion, interpenetration and
entanglement of these formulations with hydrated mucin on the
surface of the disk.
41 Although there were small differences in
mucoadhesive ability of PC and Gantrez S97 formulations, more
importantly signiﬁcant differences were observed between RSVs
and a commercially available vaginal formulation, Replens.
Moreover, RSVs displayed improved rheological properties that,
when combined with the high mucoadhesiveness, may render
these systems more acceptable.
The use of mucoadhesive polymers is a viable method of
improving the residence time of vaginal gels. However, the
design of mucoadhesive drug delivery systems with increased
residence time and resistance to in vivo stresses will only be
advantageous if the therapeutic agent is released over the
retention period. In vitro drug dissolution demonstrated that all
formulations provided sustained release of the model soluble
drug EG. The variability in the dissolution proﬁles may be
ascribed to the subtle rheological differences and, hence, the
ability of the formulation to resist ﬂuid ingress and thus
dissolution of the active from the polymer matrix. The PC
formulations that were more resistant to dilution effects by SVF
also had signiﬁcantly lower percent release at deﬁned time
intervals (Table 1). It was also noted during the dissolution study
that PC formulations had a tendency to swell, whereas the
Gantrez S97 did not. This may be attributed to the cross-linked
nature of the PC component of the gels that allows the gel bolus
to imbibe water without undergoing dissolution. Consequently,
PC formulations would be less susceptible to dissolution and
erosion and, hence, decreased release of EG.
42 The release
exponent, n, indicative of the mechanism of drug release, was
characteristic of anomalous transport; n was in the range 0.74
( 0.02 - 0.80 ( 0.06. This is typical for gels wherein a number
of competing processes are occurring during drug dissolution.
43
Conclusion
Due to their low cost, ease of manufacture, and precedence
of use in the topical administration of drugs, conventional gel
systems are commonly employed to administer drugs via the
vaginal route, mainly for the treatment of vaginal infection,
contraception, and hormone replacement therapy. More recently,
gel-based formulations are being widely developed for sustained
delivery of HIV microbicides and mucosal vaccines. The
retention of vaginal gel formulations is fundamental to the
improvement of clinical performance. Poor vaginal retention
2434 Biomacromolecules, Vol. 10, No. 9, 2009 Andrews et al.of conventional gel formulations represents a signiﬁcant chal-
lenge for those clinical indications where sustained delivery
would enhance efﬁcacy. This challenge is particularly pertinent
for the HIV microbicide ﬁeld, where coitially independent
formulations are considered essential to overcome the potential
issues surrounding user acceptability and compliance. Gels
designed for this purpose should exhibit acceptable mechanical
and rheological properties to ensure ease of application and
retention. In this study, gels composed of interactive polymeric
components have been formulated and the rheological, mechan-
ical, mucoadhesive, and drug dissolution properties have been
characterized. The dynamic (nondestructive) rheological proper-
ties following dilution, to simulate in vivo conditions, have also
been investigated. RSVs displayed a wide range of mucoadhe-
sive, mechanical (hardness, compressibility, and syringeability),
and rheological (ﬂow and dynamic) properties that were
signiﬁcantly affected by the mucoadhesive used (PC or Gantrez
S97) and also the inclusion of a thermo-gelling polymer (PL).
It is suggested that the rheologically structured gels described
in this study possess suitable properties, even following dilution,
to enhance clinical performance. In particular, the highly elastic
structure of the PC formulations after dilution, the acceptable
ﬂow and mucoadhesive properties (thereby enabling ease of
administration and retention) and the controlled release char-
acteristics may provide signiﬁcant clinical promise.
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